Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy

被引:24
作者
Abuqbeitah, Mohammad [1 ]
Demir, Mustafa [1 ]
Uslu-Besli, Lebriz [1 ]
Yeyin, Nami [1 ]
Sonmezoglu, Kerim [1 ]
机构
[1] Istanbul Univ, Cerrahpasa Fac Med, Dept Nucl Med, Istanbul, Turkey
关键词
Lu-177-DOTATATE; Lu-177-PSMA; Radiation exposure; Dose rate; Blood clearance; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS; RECEPTOR;
D O I
10.1007/s00411-017-0721-6
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The main target of this work is to examine blood clearance and external exposure for Lu-177-DOTATATE compared with new emerging Lu-177-PSMA therapy. Blood clearance and radiation exposure of 31 patients treated with 5.5 +/- 1.1 GBq Lu-177-DOTATATE were compared to those of 23 patients treated with 7.4 GBq Lu-177-PSMA. Dose rates were measured at several distances and time points up to 120 h after treatment. Blood samples were collected conjunctively after infusion. Caregiver's cumulative dose was measured by means of an OSL (optically stimulated luminescence) dosimeter for 4-5 days and medical staff's dose was also estimated using electronic personal dosimeters. Finger dose was determined via ring TLD (Thermoluminescence Dosimeter) for radiopharmacists and nurses. Dose rates due to Lu-177-DOTATATE at a distance of 1 m, 4 h and 6 h after infusion, were 3.0 +/- 2.8 and 2 +/- 1.9 A mu Sv/(h GBq), respectively, while those due to Lu-177-PSMA were 3.1 +/- 0.8 and 2.2 +/- 0.9 A mu Sv/(h GBq). Total effective dose of 17 caregivers was 100-200 A mu Sv for Lu-177-DOTATATE therapy. Mean effective doses to nurses and radiopharmacists were 5 and 4 A mu Sv per patient, respectively, while those for physicists and physicians were 2 A mu Sv per patient. For Lu-177-DOTATATE, effective half-life in blood and early elimination phase were 0.31 +/- 0.13 and 4.5 +/- 1 h, while they were found as 0.4 +/- 0.1 and 5 +/- 1 h, respectively, for Lu-177-PSMA. The first micturition time following Lu-177-DOTATATE infusion was noted after 36 +/- 14 min, while the second and third voiding times were after 74 +/- 9 and 128 +/- 41 min, respectively. It is concluded that blood clearance and radiation exposure for Lu-177-DOTATATE are very similar to those for Lu-177-PSMA, and both treatment modalities are reasonably reliable for outpatient treatment, since the mean dose rate [2.1 A mu Sv/(h GBq)] decreased below the dose rate that allows release of the patient from the hospital (20 A mu Sv/h) after 6 h at 1 m distance.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 14 条
[1]  
Bakker WH, 2006, Q J NUCL MED MOL IM, V50, P265
[2]   Evaluation of radiation safety in 177Lu-PSMA therapy and development of outpatient treatment protocol [J].
Demir, Mustafa ;
Abuqbeitah, Mohammad ;
Uslu-Besli, Lebriz ;
Yildirim, Ozlem ;
Yeyin, Nami ;
Cavdar, Iffet ;
Vatankulu, Betul ;
Gunduz, Huseyin ;
Kabasakal, Levent .
JOURNAL OF RADIOLOGICAL PROTECTION, 2016, 36 (02) :269-278
[3]  
Demir M, 2011, RADIAT PROT DOSIM, V147, P528, DOI 10.1093/rpd/ncq497
[4]   TECHNIQUE FOR THE ABSOLUTE MEASUREMENT OF ACTIVITY USING A GAMMA-CAMERA AND COMPUTER [J].
FLEMING, JS .
PHYSICS IN MEDICINE AND BIOLOGY, 1979, 24 (01) :176-180
[5]  
International Commission on Radiological Protection, 1990, ICRP PUBL, P1
[6]   Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer [J].
Kabasakal, Levent ;
AbuQbeitah, Mohammad ;
Aygun, Aslan ;
Yeyin, Nami ;
Ocak, Meltem ;
Demirci, Emre ;
Toklu, Turkay .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (13) :1976-1983
[7]   Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors [J].
Kwekkeboom, Dik J. ;
Kam, Boen L. ;
van Essen, Martijn ;
Teunissen, Jaap J. M. ;
van Eijck, Casper H. J. ;
Valkema, Roelf ;
de Jong, Marion ;
de Herder, Wouter W. ;
Krenning, Eric P. .
ENDOCRINE-RELATED CANCER, 2010, 17 (01) :R53-R73
[8]   [177Lu-DOTA0,Tyr3]octreotate:: comparison with [111In-DTPA0]octreotide in patients [J].
Kwekkeboom, DJ ;
Bakker, WH ;
Kooij, PPM ;
Konijnenberg, MW ;
Srinivasan, A ;
Erion, JL ;
Schmidt, MA ;
Bugaj, JL ;
de Jong, M ;
Krenning, EP .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (09) :1319-1325
[9]  
Marriott CJ, 2007, RADIAT PROT DOSIM, V123, P62, DOI [10.1093/rpd/ncl084, 10.1093/rpd/nc1084]
[10]   Localisation and mechanism of renal retention of radiolabelled somatostatin analogues [J].
Melis, M ;
Krenning, EP ;
Bernard, BG ;
Barone, R ;
Visser, TJ ;
de Jong, M .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (10) :1136-1143